Baboon TLR3 Polynucleotides for Cross-Reactivity Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to develop TLR3 modulators for human use face challenges in cross-reactivity across species, necessitating the identification of suitable animal models expressing TLR3 with high identity and homology to human TLR3 for predictive pharmacokinetic, safety, and efficacy studies.
Innovation Solution
The use of Papio cynocephalus (Yellow Baboon) Toll-Like Receptor 3 (TLR3) polynucleotides, vectors, host cells, and polypeptides to express TLR3 proteins and generate therapeutic antibodies, facilitating the assessment of TLR3 modulators' safety and cross-reactivity, and enabling the modulation of TLR3 activity for various therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TLR3 modulators are developed for human use, then therapeutic efficacy is improved, but species cross-reactivity challenges worsen
Solution Approach 1:
The patent uses baboon TLR3 as an intermediary model system that bridges human TLR3 research and preclinical testing. The baboon TLR3 shares high sequence identity with human TLR3, allowing modulators developed against human TLR3 to effectively bind and modulate baboon TLR3, thereby enabling reliable prediction of human therapeutic responses while avoiding direct human testing limitations
Solution Approach 2:
The patent creates a copy of the human TLR3 system using baboon TLR3, which replicates the key functional and structural characteristics of human TLR3. This copying approach allows researchers to study TLR3 modulator interactions, signaling pathways, and therapeutic effects in a living system that closely mimics human biology, thereby resolving the cross-reactivity challenge between species
2Measurement precision
If animal models with high TLR3 homology to human are selected, then predictive accuracy for human responses is improved, but model identification and validation complexity worsens
Solution Approach 1:
The patent performs preliminary sequencing and homology analysis to identify baboon TLR3 as a suitable model before conducting extensive preclinical studies. By预先 establishing the high sequence identity (95.7% at protein level, 94.8% at nucleotide level) between baboon and human TLR3, the patent simplifies subsequent model validation and reduces the complexity of proving predictive accuracy in later therapeutic development stages
Data Source
Figure 1
Figure 1
Figure 2
AI summary
Isolated polynucleotides encoding Papio cynocephalus Toll- Like Receptor 3 (Baboon TLR3), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.